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Abstract
Bacterial nitroreductases (NTRs) have been widely utilized in the development of novel anti-
biotics, degradation of pollutants, and gene-directed enzyme prodrug therapy (GDEPT) of
cancer that reached clinical trials. In case of GDEPT, since NTR is not naturally present in
mammalian cells, the prodrug is activated selectively in NTR-transformed cancer cells,
allowing high efficiency treatment of tumors. Currently, no bioluminescent probes exist for
sensitive, non-invasive imaging of NTR expression. We therefore developed a "NTR caged
luciferin" (NCL) probe that is selectively reduced by NTR, producing light proportional to the
NTR activity. Here we report successful application of this probe for imaging of NTR in vitro,
in bacteria and cancer cells, as well as in vivo in mouse models of bacterial infection and
NTR-expressing tumor xenografts. This novel tool should significantly accelerate the devel-
opment of cancer therapy approaches based on GDEPT and other fields where NTR
expression is important.
Introduction
The nitroreductase (NTR) family of enzymes are widespread amongst bacteria and are known
to metabolize nitrosubstituted compounds and quinones using NADH or NADPH as reducing
agents [1–4]. They are important for the development of novel antibiotics being the main target
for the treatment of infections caused by bacteria, e.g.Mycobacterium tuberculosis [5],Helico-
bacter pylori [6] and by parasites, e.g. Trypanosoma [7], Giardia and Entamoeba [8]. Their
enzymatic activity in gut microbiota is linked to carcinogen production and etiology of colorec-
tal cancer [9,10]. In addition, they are used in biotechnology for degradation of environmental
contaminants [1]. Due to their absence in mammalian cells they are also utilized as activating
enzymes in gene-directed enzyme prodrug therapy (GDEPT) approaches for cancer
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chemotherapy [11] where the NTR gene is used to selectively transform cancer cells, providing
unique targeted therapy of tumors over normal tissues [12]. Nitroaromatic prodrug CB1954 in
the complex with bacterial NTR is promising for GDEPT and has reached clinical trials for
prostate cancer [13].
Following the recent first approval in Europe of a gene therapy medicine, the potential for
clinical application of GDEPT is increasing [14]. However, both preclinical and clinical devel-
opment of NTR-based GDEPT systems has been severely hampered by the lack of imaging
tools that allow sensitive in vivo evaluation of transgene expression in living subjects. Quantifi-
cation of the level of transgene expression is extremely important because it is directly linked to
the effectiveness of the therapy.
Bioluminescence (BL) is currently the most sensitive optical in vivo imaging modality avail-
able, and has been applied to visualize multiple biological processes in small animals [15,16]. It
obviates most of the limitations of in vivo fluorescent imaging [17], such as high tissue-derived
autofluorescence, photobleaching, limited tissue penetration and lack of quantification.
Several activatable fluorescent probes for NTR imaging in vitro have been previously described
[18–22]. However, the only reported probe for imaging of NTR in vivo relies on fluorescence
(CytoCy5S) [23–25] and therefore possesses the limitations mentioned above.
Similar to bioluminescent imaging, in vivo chemiluminescent imaging offers the advantages
of high sensitivity due to low background and high signal-to-noise ratios. Prior studies have
elegantly demonstrated the application of chemiluminescence for imaging of myeloperoxidase
activity [26] and beta-galactosidase activity [27] in vivo. However, although chemilumines-
cence has the additional advantage of not requiring luciferase transfected cells for the genera-
tion of light, expression of this enzyme allows more elaborate disease models to be developed
due to the researcher’s ability to define its spatial localization and regulation. Moreover, most
chemiluminescent agents suffer from low quantum yield, short maximal photon wavelength
emission and high instability. For example, the quantum yield of aqueous luminol chemilumi-
nescence is 1.23 ± 0.20% [28] with a maximal emission of 424 nm [29], while the reported
quantum yield of firefly BL is 41.0 ± 7.4% [30], that is about 40 times higher, with D-
hydroxyluciferin and D-aminoluciferin having wavelength at 560 nm and 603 nm respectively
[31]. Recently, Zhang et al. [32] showed the advantage of using both near-infrared fluorescent
and chemiluminescent imaging in combination, while addressing the wavelength issue associ-
ated with luminol chemiluminescence in vivo by shifting it into the near-infrared region utiliz-
ing quantum dots.
BL is based on the interaction of a small molecule D-luciferin with firefly luciferase that
results in the generation of photons of light. The system can be "tuned" through "caging" of the
luciferin scaffold to image and quantify activities of biological molecules. Target-mediated
selective removal of the caging moiety leads to production of free D-luciferin and subsequent
generation of photons by luciferase, that can be quantified [33]. While this strategy was previ-
ously used by us and others to study biological processes (delivery and biodistribution of cell-
penetrating peptide conjugates [34], cell surface glycosylation [35], hydrogen peroxide fluxes
[36], fatty acids uptake [37]) and image enzyme activity (beta-galactosidase [38], caspases
[39–41], furin [42] and beta-lactamase [43], no bioluminescent probes have been previously
reported for imaging of NTR. Here, we describe the development of novel NTR-specific biolu-
minescent probe, termed Nitroreductase Caged Luciferin (NCL). Our results demonstrate
that this probe can be used for non-invasive real-time imaging of NTR activity in vitro, in
live bacteria and mammalian cells, as well as in preclinical models of cancer and bacterial
infection.
Bioluminescent NTR Probe for Preclinical Imaging
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Materials and Methods
Chemical materials and synthesis
The synthetic procedures and characterization are detailed in the S1 File.
Kinetics of NCL reaction with NTR by fluorescence
Fluorescence was measured using a Tecan Infinite M1000 (Tecan Austria GmbH) plate reader.
Kinetic measurements of NCL (5–50 μM) uncaging by NTR (0.25 μg mL-1) were performed in
the presence of NADH (500 μM) at 37°C in PBS buffer (pH 7.4). The kinetics rate of luciferin
release from NCL was measured by fluorescence at 330 nm excitation and 530 nm emission
wavelengths. The fluorescence calibration curve for luciferin was used to calculate the rate
(S2 Fig). Kinetic parameters Km and Vmax were determined fromMichaelis-Menten model and
Lineweaver-Burk plot was used to display the data. The kcat value was calculated by dividing
the Vmax value, obtained from the data acquired for the determination of the corresponding
Km values for the probe, by the concentration of the nitroreductase in the assay.
Inhibition assay of NTR by dicoumarol in enzyme assay
NCL (20 μM) uncaging by NTR (0.5 μg mL-1) in the presence of NADH (100 μM) was inhib-
ited by various concentrations of dicoumarol (0 to 200 μM). Luciferin release from NCL was
measured by fluorescence at 330 nm excitation and 530 nm emission wavelengths over time.
Inhibitory activity of dicoumarol is expressed as a percentage compared to uninhibited control
(S3 Fig).
Bioluminescent imaging of NTR with NCL in enzyme assay
In vitro imaging studies were performed in clear bottom black 96 well plates from Becton Dick-
inson and Company. An IVIS Spectrum (PerkinElmer) was used to measure the amount of
bioluminescent imaging (BLI) signal production. The data are presented as pseudocolor images
indicating light intensity (red being the most intense and blue the least intense), which are
superimposed over the grayscale reference photographs. Bioluminescence was quantified using
region of interest (ROI) analysis of individual wells and the average signal expressed as the
total number of photons emitted per second per cm2 per steradian (p/sec/cm2/sr) from each of
the three wells was calculated by using the Living Image software. Total luminescence was cal-
culated by integrating the area under corresponding kinetic curves. Luciferase buffer was pre-
pared as following: 2 mM ATP, 5 mMMgSO4 in PBS (pH 7.4). Stock solutions of luciferase in
luciferase buffer, NADH, NCL, luciferin and NTR in PBS (pH 7.4), were freshly prepared and
aliquoted in a 96-well plate to give the following final concentrations in the total volume of
100 μL/well: luciferase (60 μg mL-1), NADH (100 μM), NTR (10 μg mL-1), luciferin or NCL
(0.25–5 μM); luciferin and NCL were added at the last step with a multichannel pipette from
the additional 96-well plate. Bioluminescence signal from the plate was acquired immediately
every 1 min with 0.5 s integration time for 30 min.
Bacterial strains, plasmids and culture conditions
E. coli K-12 MG1655 (- luc gene) and E. coli K-12 AB1157, containing the luciferase expressing
pUC57 Click beetle red (CBR) plasmid (+ luc gene) was a kind gift from Daniel Ansaldi (Per-
kin Elmer). The NTR triple mutant, E. coli K-12 AB502NemA, was a kind gift from Dr. Anto-
nio Valle (University of Cádiz, Cádiz, Spain) and was transformed with the pUC57 CBR
plasmid for production of luciferase. E. coliMG1655 lux, expressing lux luciferase, was
Bioluminescent NTR Probe for Preclinical Imaging
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generated as previously described [44]. All strains were grown aerobically at 37°C in Luria Ber-
tani (LB) medium supplemented with 100 μg mL-1 ampicillin (Amp).
Bioluminescent imaging of NTR activity by NCL in E. coli
An IVIS-100 (PerkinElmer) was used to measure the amount of BLI signal production. Stock
solutions of luciferin and NCL in PBS (pH 7.4) were freshly prepared and aliquoted in a
96-well plate to give the final concentrations (1–250 μM) in the total volume of 200 μL/well.
The volume of bacterial suspension was 150 μL/well. Bioluminescence signal from the plate
was acquired immediately every 2 min with 10 s integration time for 1 h.
Cell lines and cell culture
Cell line MDA-MB-231-NTR-Fluc-EGFP (NTR+luc+) used for in vitro and in vivo experi-
ments in this study was kindly provided by Dr. Ramasamy Paulmurugan (Stanford University
School of Medicine, Stanford, USA) [25]. The cells were generated as described below with a
reference to Sekar et al. [25]. The cloning vectors, expressing bacterial nitroreductase gene
(NTR2) and Fluc-EGFP fusion constructs, were from the plasmid bank (Cellular Pathway
Imaging Laboratory, Stanford). To make MDA-MB-231 stable cell line, modified pcDNA3.1
(PURO) vector expressing NTR was transfected using Lipofectamine 2000 Transfection
Reagent (Invitrogen). 24 hours later medium was changed and the cells were treated with
100 ng mL-1 of puromycin. The process was continued until no further cell death was observed.
The cells were plated in low dilution (1 cell/100 μL) in a 96 well plate. Single colonies of cells
expressing NTR were expanded for further transduction with lentivirus expressing Fluc-EGFP
fusion protein. To control the level of Fluc-EGFP at near equal expression, cells were sorted by
FACS in a similar window after transduction. MDA-MB-231 stable cells were maintained in
puromycin stress throughout the study. Single colonies of stable cells were evaluated for the
functionality of NTR enzyme by incubating with a CytoCy5S (red-shifted NTR substrate; GE
Healthcare) for the detection of fluorescent signal (λex/em = 628 nm/ 638 nm).
Cell line MDA-MB-231-luc-D3H2LN Bioware (NTR-luc+), used as NTR negative control
for in vitro and in vivo experiments in this study, was purchased from PerkinElmer, and main-
tained in Dulbecco’s Modified Eagle’s Medium supplemented with 10% (v/v) heat-inactivated
FBS, 1% (v/v) penicillin/streptomycin (all reagents purchased from Life Technologies).
Bioluminescent imaging of NTR by NCL in stable cell lines
MDA-MB-231-NTR-Fluc-EGFP cells and control MDA-MB-231-luc cells were plated at a
density 3 × 104 cells/well in two black 96-well plates with clear bottom, after 48 h the growth
medium was removed, and 100 μL of NCL probe or luciferin solutions (1–100 μM) in cell cul-
ture medium was added to the wells. The plates were immediately placed in IVIS Spectrum
and were imaged every 1 min for 1 h. Observed BLI signal was quantified using ROI analysis
with Living Image software.
Ethics statement
All animal procedures on imaging of bacterial NTR in a mouse model of thigh infection were
performed in accordance with the national ethical guidelines prescribed by the Health Products
Regulatory Authority (HPRA). Protocols were approved by the animal ethics committee of
University College Cork (AERR #2010/003 and #2012/015). Experiments on imaging of NTR
in a mouse model of subcutaneous cancer were carried out in strict accordance to the Swiss reg-
ulation on animal experimentation and the protocol (#2363) was approved by the authority of
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the Canton Vaud, Switzerland (EXPANIM (Expérience sur animaux)–SCAV, Département de
la sécurité et de l’environnement, Service de la consommation et des affaires vétérinaires). All
efforts were made to minimize suffering.
Bacterial administration and imaging of bacterial nitroreductase in mice
Bacteria were grown at 37°C in a shaking incubator until reaching OD600 of 0.6 in LB medium,
containing 100 μg mL-1 Amp. Cultures were harvested by centrifugation (4000 × g for 10 min)
and washed three times in PBS. After washing, bacteria were resuspended in one tenth volume
of PBS. Mice were kept at a constant room temperature (22°C) with a natural day/night light
cycle in a conventional animal colony. Standard laboratory food and water were provided ad
libitum. Mice were afforded an adaptation period of at least 7 days before the beginning of
experiments. Female BALB/c mice (Harlan, Oxfordshire, UK) in good condition, without
infections, weighing 18–22 g and 6–8 weeks old, were kept as previously described [45] and
were included in experiments. BALB/c mice were anaesthetized and the fur on the rear legs
was removed. Mice were injected directly into the right quadriceps muscle at a depth of
approximately 5 mm with 50 μL of bacteria suspended in PBS. The concentration of bacterial
suspensions used for injection ranged from 106 to 109 bacteria/mL. Mice also received an intra-
muscular injection of 50 μL sterile PBS in the left rear quadriceps (control) and lux MG1655
E. coli (positive control). 1 h post bacterial injection, mice received an IP injection of 200 μL of
10 mMNCL probe (0.8 mg) or 200 μL of 10 mM D-luciferin potassium salt (0.63 mg) in PBS.
For in vivo experiments involving varying concentrations of the probe, the concentration of
NCL probe injected was 200 μL of 1, 10 or 20 mM solutions in PBS (0.08, 0.8 or 1.6 mg of NCL
probe). Mice were imaged for bioluminescence at regular intervals beginning immediately after
probe injection using IVIS 100. Mice that were infected with bacteria for experimental pur-
poses were monitored for signs of illness for the duration of the experiment. No adverse symp-
toms were reported. Following bioluminescence imaging, or at experiment end, animals were
euthanized by cervical dislocation.
Mice and tumor induction
Swiss nu/nu mice were obtained from Charles River Labs. Mice were maintained at the EPFL
UDP animal facility under pathogen free conditions and group housed in individually venti-
lated cages at 22°C with 12/12 light cycle. Before experiments the mice were afforded an adap-
tation period of at least 7 days. Female mice in good condition, weighing 18–25 g and 6 weeks
of age were randomly divided in two experimental groups (n = 5 per group). For tumor induc-
tion, 1 × 106 cells in 100 μL of FBS-free medium/Matrigel (BD Biosciences) (50:50) was injected
subcutaneously into the flank of the mice. One group was injected with MDA-MB-
231-NTR-Fluc-EGFP cells and the other group- with MDA-MB-231-luc cell (control). The via-
bility of cells used for inoculation was more than 95% as determined by Trypan Blue Dye
Exclusion (Gibco). Following tumor establishment, the health parameters that may lead to the
endpoints were carefully monitored in xenograft mice three times a week: cachexia (acute
weight loss), lack of activity and loss of appetite. Weight was measured and general behavior as
well as body conditions was assessed. Tumor size was carefully monitored to ensure that it
doesn’t exceed maximal allowed size of 1 cm3. Tumor volume was measured by caliper and cal-
culated according to the formula 1/2(length × width2). When tumors reached approximately
0.1 cm3 in volume, the mice were imaged with luciferin (1.5 mg/mouse in 50 μL of PBS IP) for
1 h once a week to estimate the light emission and the optimal imaging window. Biolumines-
cence was acquired using IVIS Spectrum, every 1 min for 1 h with the auto-exposure mode.
Bioluminescent NTR Probe for Preclinical Imaging
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Following bioluminescence imaging at experiment end animals were euthanized by CO2 inha-
lation or cervical dislocation.
Imaging of nitroreductase in a mouse model of subcutaneous cancer
Potassium salt of D-luciferin (Intrace Medical) was dissolved in PBS (pH 7.2), solution was fil-
ter sterilized through 0.22 μm filter, aliquoted and kept at –20°C. NCL probe was dissolved in
PEG400 (Sigma-Aldrich) and diluted with sterile PBS (pH 7.2) 1:5 (20% (v/v) of PEG400 in the
total volume of 200 μL), fresh solution was prepared before every imaging. The dose of NCL
probe (1.9 mg/mouse) was equivalent (4.7 μmol) to the dose of luciferin (1.5 mg/mouse). Mice
were anesthetized prior to injection and during imaging via inhalation of isoflurane (Piramal
Critical Care, Inc). When the total photon flux over 1 h from the mice imaged with luciferin
reached 1 × 108, the mice entered the experiment. On day 1 of the experiment all mice were
injected IP with luciferin (1.5 mg/mouse in 50 μL of PBS) and bioluminescence was acquired
immediately every 1 min for 1 h with the auto-exposure mode. On day 2 of the experiment (24
h after the luciferin imaging) all mice were injected IP with NCL probe (1.9 mg/mouse in
200 μL of PBS containing 20% (v/v) PEG400) and bioluminescence was acquired immediately
every 1 min for 1 h with the auto-exposure mode.
Data analysis from a cancer model experiment
Bioluminescence was quantified using ROI analysis of the tumor area individually for each
mouse. Total luminescence was calculated by integrating the area under corresponding kinetic
curves. Percent of the NCL probe uncaging was calculated individually for each mouse using
the formula:
% of uncaging ¼ Total photon flux over 1 h from NCL  100%
Total photon flux over 1 h from luciferin
Statistical analysis
Two-tailed Student’s t-test was used to determine statistical significance (GraphPad Prism
6.03, GraphPad Software).
Results and Discussion
Probe design
The reduction of nitroaromatic compounds can occur through one- or two-electron mecha-
nism [1]. Two types of bacterial NTRs have been described and they are classified according to
the oxygen dependence. The NTRs used in our study (NfsA, NfsB) are type I oxygen-insensi-
tive NTRs, they catalyze the reduction of the nitro group by addition of a pair of electrons, and
their activity does not depend on the level of oxygen. However, the oxygen-sensitive NTRs
(type II) catalyze the reduction of the nitro group by the addition of one electron, forming the
nitro anion radical, which is oxidized back to the nitro group by oxygen. Bacteria contain both
types of nitroreductases with type I being the most characterized among other NTRs. The inde-
pendence of reduction from the level of oxygen in E. coli had been previously demonstrated for
an NTR-sensitive coumarin probe (7-nitrocoumarin-3-carboxylic acid) suggesting the preva-
lent involvement of type I NfsA and NfsB possibly along with other uncharacterized NTRs
[46].
Bioluminescent NTR Probe for Preclinical Imaging
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We have previously demonstrated the suitability of exploiting NTR activity as being suffi-
ciently selective to distinguish bacterial cells from host background [47]. Several NTR-related
enzymes have been identified in mammalian cells and they functionally relate to type I NTRs
(NAD(P)H-quinone oxidoreductase (DT-diaphorase EC 1.6.99.2) and xanthine dehydrogenase
EC 1.17.1.4). They can potentially contribute to reduction of nitroaromatics, although they are
not phylogenetically related and do not exhibit the typical domain characteristic of NTR family.
These properties were investigated in the study on FMISO imaging reagent, a derivative of
nitroimidazole used as a hypoxia PET tracer [48]. It was reported that under hypoxic conditions
xanthine dehydrogenase is converted to xanthine oxidase that reduces FMISO and other nitroi-
midazole-containing compounds. Similarly, eukaryotic NTRs that are functionally related to
type II (aldehyde oxidase EC 1.2.3.1, cytochrome c oxidase EC 1.9.3.1, and NADPH cytochrome
P450 reductase EC 1.6.2.4) can potentially reduce nitroaromatics anaerobically and are generally
used as targets for hypoxia-activated prodrugs and imaging agents [49].
Therefore, several important factors need to be taken into account when designing the com-
pounds activated selectively by bacterial or mammalian enzymes. For bacterial NTRs the activa-
tion is largely dependent on the redox potential of the nitroaromatics. For example, nitrofurans
display relatively high redox potentials (reported from -250 to -270 mV) and are reductively acti-
vated by NAD(P)H nitroreductases of enteric bacteria. At the same time metronidazole (nitroi-
midazole) is only activated by anaerobic enzymes showing low redox potentials (-480 mV) in
some bacteria and protozoa, making it well tolerated in humans when used as an antibiotic [50].
Substrate specificity of the designed compounds is also important, for example CB 1954
prodrug is efficiently reduced by bacterial NTRs and a human DT-diaphorase (NQO2) while
being a poor substrate for a human paralogue NQO1 enzyme [51]. These and other important
aspects of selectivity of bioreductive prodrugs are discussed in more details in a recent review
by Wilson and Hay [52].
The overall probe design is based on caging of D-luciferin with nitrofuryl moiety resulting
in "Nitroreductase Caged Luciferin" (NCL) probe (Fig 1). 5-Nitrofuryl was selected as a cage as
its derivatives (nitrofurazone, nitrofurantoin) were shown to be efficiently activated by NTR in
bacteria [50]. Upon the reduction of the nitro group by NTR the resulting electron-donating
amino group promotes the cleavage of the C-O bond (uncaging), leading to the subsequent
release of luciferin which is oxidized by luciferase and a photon of light is emitted. Therefore,
release of free luciferin followed by light production is only possible in the presence of NTR.
Fig 1. General strategy for imaging of NTR activity with Nitroreductase Caged Luciferin (NCL) probe.
doi:10.1371/journal.pone.0131037.g001
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Bioreductive activation of NCL in cell-free assays
We first investigated the specificity of probe uncaging by incubating NCL with a recombinant
NTR enzyme from E. coli (NfsA) in the presence of NADH as a cofactor. The release of lucif-
erin was followed by HPLC-MS analysis as a function of time (S1 Fig). The resulting data dem-
onstrated rapid conversion of NCL into free luciferin under these conditions, the calculated
values of rate constant and NCL half-life, were 5.8 × 10-3 s-1 and 119.5 s respectively (S1 Fig).
Next, we determined the Michaelis-Menten kinetic parameters for the NTR-specific cleav-
age of NCL probe (S2 Fig) using fluorescence to monitor release of luciferin (λex/em = 330/530
nm) as the caged probe is not fluorescent. Both Vmax and Km values were found to be compara-
ble to those previously reported for a NTR fluorescent substrate [20] and were determined to
be 0.057 μM s-1 and 24.7 μM respectively. Catalytic efficiency of probe reduction by NTR (kcat/
Km) was determined to be 2.25 × 10
7 M-1 s-1, which is two orders higher than that of luciferin-
luciferase reaction (1.07 × 105 M-1 s-1) [53]. To evaluate if the probe can be used as a reporter
of NTR activity, we investigated the effect of the NTR inhibitor dicoumarol (competitive with
NADH) on the efficiency of NCL uncaging. A gradual concentration-dependent decrease in
signal was observed (Fig 2A) indicating that the uncaging of NCL depends on the activity of
NTR. We also assayed quantitative capability of the probe against the amount of NTR by fluo-
rescence and found the detection limit to be 0.15 μg/mL (S2 Fig).
To determine the utility of NCL as a bioluminescent reporter, we measured the light emis-
sion from increasing concentrations of NCL (0.25–5 μM) in the presence or absence of NTR
and firefly luciferase (Fig 2B). The resulting signal was concentration-dependent and no signifi-
cant light was produced in the absence of NTR, resulting in high signal to background noise
ratios even at relatively low concentrations of the probe in comparison to that previously
reported [36,42]. In addition, NCL demonstrated an average 70% conversion into luciferin, the
highest uncaging efficiency among existing caged luciferin substrates reported to date [36,42].
We also verified that NTR did not have any effect on the luciferin-luciferase reaction (S4 Fig).
Imaging of NTR activity in E. coli
We approached the validation of NCL in a live biological system initially utilizing bacteria as a
source of both NTR and luciferase. We investigated the potential of NCL probe for imaging
NTR in E. coli naturally expressing NTR [2–4] and engineered to express luciferase. The result-
ing signal from NCL or luciferin control was compared between several E. coli strains: 1) E. coli
Fig 2. Evaluation of NTR-specific uncaging of NCL probe. (A) NCL (20 μM) uncaging by NTR (0.5 μg mL-
1) in the presence of NADH (100 μM) was inhibited by dicoumarol (0 to 200 μM). (B) Total luminescence over
30 min from luciferin or NCL (0.25–5 μM) with NADH, luciferase, and NTR, compared with the control (no
NTR), *P < 0.001.
doi:10.1371/journal.pone.0131037.g002
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wt, 2) E. coli engineered to stably express luciferase (E. coli luc+), 3) a strain of E. coli (NTR KO
luc+) with three well-described NTR genes knocked out (NfsA, NfsB and NemA). First, as
shown on Fig 3A, significant signal above background was detected from E. coli luc+ in com-
parison with E. coli wt, indicating the need of luciferase presence for light production. Both wt
and NTR KO luc+ strains showed similar levels of luciferase expression when treated with lucif-
erin. However with NCL the signal from parent strain was significantly higher than from the
NTR mutant strain (NTR KO luc+), demonstrating probe selectivity for detection of NTR
activity in bacteria. The presence of a signal in wells with NTR KO luc+ strain indicates that
reduction of the nitrofuryl cage is not exclusive or specific to any of the three major E. coli
NTRs (NfsA, NfsB and NemA) and that cage reduction can be achieved at detectable levels in
the presence of the remaining NTRs in E. coli. In E.coli, several nitroreductases (NfsA [2], NfsB
[3], YdjA [4]) and reductases (NemA [54]) are characterized, while the exact functions of other
reductase proteins remain unclear. Recent studies [4] indicate that E. coli reductases could also
have additional nitroreductase activity.
Fig 3. Light production in E. coli by NTR-mediated uncaging of NCL. (A). Light output from NCL (300 μM) after 2 h incubation in luciferase-expressing E.
coli (+ luc gene) is significantly higher than in NTRmutant (NTR KO luc+) (*P < 0.001) and in wild type (- luc gene). The dashed line indicates the
background. (B). Overlay of a photographic image and bioluminescence from the assay described. (C). Bioluminescence from 100 μMNCL probe and
luciferin incubated with various concentrations of luciferase expressing E.coli AB1157 (102–108 bacteria mL-1) for 10 min before imaging. (D).
Bioluminescence from luciferase expressing E.coli luc+ (108 bacteria mL-1) incubated with various concentrations of NCL or luciferin (1–250 μM) for 10 min
before imaging.
doi:10.1371/journal.pone.0131037.g003
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We also investigated the signal dependence on different numbers of bacteria and significant
signals were evident at concentrations of bacteria as low as 104 cells/mL (1.5 × 103 cells/well)
(Fig 3C). The average efficiency of probe uncaging in bacteria was calculated to be 35% (Fig 3D).
Stability profiling
Since an ideal imaging reagent should be non-toxic and stable in biological environments, we
next investigated these parameters. The probe did not induce any toxicity in bacteria or mam-
malian cells (S10 Fig). The half-life of NCL in mouse plasma in vitro was determined to be 53.7
h (S6 Fig), which readily permits robust BL imaging in vivo. In addition, NCL demonstrated
excellent stability to liver microsomes in vitro (S7 Fig).
Imaging of bacterial NTR in vivo in a mouse model of intramuscular
infection
The utility, and importantly, the specificity, of the probe in vivo was examined in a mouse
model of thigh muscle infection, again utilizing bacteria as the source of both NTR and lucifer-
ase. Balb/c mice were injected in quadriceps with various numbers of E.coli luc+ (5 × 104–
5 × 107), followed by IP injection of NCL 30 min later (Fig 4A). Animals were imaged at vari-
ous time points over 24 h (Fig 4C). Signal from the probe was detected 20 min post injection
lasting for as long as 24 h and correlated with the amount of probe injected. The intensity
increased over the first 4 h reaching plateau afterwards. The total photon flux produced during
this time was approximately 1/3 of the total flux detected from the mice injected with luciferin,
demonstrating high efficiency of uncaging by bacterial NTR in vivo (Fig 4B). We also com-
pared the probe kinetics after different administration routes in mouse model of E. coli intra-
muscular infection (S8 Fig). Statistical analysis of the data showed no significant difference in
signal from IP and IV administration of the probe in this model.
Evaluation of NCL in NTR expressing cancer cells
As the next step we applied NCL for imaging of NTR activity in breast cancer cells, stably
transfected with NTR and luciferase (MDA-MB-231-NTR+luc+) [25]. The expression of active
NTR was confirmed by using the previously described NTR-specific fluorescent CytoCy5S
probe (S9 Fig). Addition of different concentrations of NCL to NTR+ cells resulted in rapid
concentration-dependent signal increase, with up to 40 times signal-to-noise ratio at the high-
est concentration used (100 μM) (Fig 5A). Contrary to this, NTR- cells produced much lower
signal of equal intensity at all concentrations used (Fig 5B). The difference in brightness
between the two cell lines due to different expression levels of luciferase was taken into account
by normalizing the signal from NCL to the signal from equimolar quantities of luciferin con-
trol. The selectivity of NCL uncaging was also tested in another NTR-/NTR+ cancer cell line
and similar results were observed (S11 Fig).
The difference in kinetics of the signal from the probe in bacteria (Fig 4) and mammalian
cells (Fig 5) can be explained by the fact that E. coli naturally expresses several types of nitrore-
ductases, while the mammalian cell line used in our experiments was transfected with one type
of nitroreductase.
Imaging of NTR activity in subcutaneous xenograft model of cancer
In light of these positive results we decided to investigate the utility of NCL as a reporter of
NTR activity in a cancer xenograft model in mice, using the same cell lines previously validated
in vitro (Fig 5). Subcutaneous NTR+ or NTR- xenograft tumors were induced in two groups of
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Fig 4. In vivo activation of NCL probe by luciferase and nitroredictase expressing E.coli in a mousemodel of thigh infection. (A). Luminescence over
4 h from E. coli luc+ infected quadriceps (5 × 104–5 × 107 bacteria) after IP injection of 0.8 mg NCL probe (200 μL of 10 mM solution in PBS). (B).
Luminescence over 4 h from E. coli luc+ infected quadriceps (5 × 107 bacteria) following IP injection of 0.8 mg of probe or 0.63 mg of luciferin (200 μL of
10 mM solution in PBS). (C). Luminescence imaging of mice over 24 h bearing 5 × 107 bacteria, treated with various (0.08, 0.8 and 1.6 mg) NCL probe
concentrations (200 μL of 1, 10 and 20 mM solutions of NCL in PBS). As a positive control, mice were injected with equal amounts of E. coliMG1655
expressing lux luciferase that doesn't require exogenous substrate for light production [44]. The signal was collected over 24 h, n = 3 per group.
doi:10.1371/journal.pone.0131037.g004
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mice (n = 5 per group) and were grown to an average volume of approximately 0.25 cm3. We
chose to implant the NTR+ and NTR- cells in different mice to ensure that the signal produced
from the probe is specific to the cell type and doesn't result from luciferin diffusion to the
neighboring tumor. Another reason to implant the cells separately was the difference in light
emission that could preclude accurate measurements for light sources of different intensity on
a single mouse.
When caged luciferin probes are used to measure the activity of a biomolecule in various
experimental settings, the light output needs to be calibrated to the amount of luciferase
[36,55,56]. In our case this calibration takes into account variations between luciferase levels in
tumors from one group to another. Therefore, in order to compare the performance of the
probe in two different cancer cell lines with a various level of luciferase expression we normal-
ized the signal from of the probe to the signal from equimolar amount of D-luciferin.
Both groups of mice were first injected IP with luciferin (1.5 mg) to determine the overall
light emission from each tumor over 1 h. This signal was later used to calculate percentage of
Fig 5. Imaging of NTR activity in cells and in in vivo cancer model with NCL. (A) Concentration-
dependent uncaging of NCL in MDA-MB-231 NTR+luc+ cancer cells in comparison with luciferin. (B)
Selectivity of NTR imaging by NCL in the same cells in comparison with NTR-luc+ cells. The dashed line
indicates background (cells only), *P = 0.0001. (C) In vivo imaging of NTR activity in subcutaneous NTR
+ and NTR- xenografts (n = 5). Total luminescence over 1 h from IP injection of luciferin (1.5 mg) and NCL
(1.9 mg). d) Representative images of mice 15 min post injection of luciferin or NCL.
doi:10.1371/journal.pone.0131037.g005
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NCL uncaging in order to normalize tumor size and level of luciferase expression from NTR-/
+ cell lines. 24 h later, all mice were injected IP with equimolar quantities of NCL (1.9 mg), fol-
lowed by collection of light over 1 h. Since the residual light from luciferin injection could con-
tribute to the signal from the probe, the absence of residual signal was verified by imaging of
mice before probe administration. The level of probe uncaging in NTR+ and NTR- groups was
determined by quantifying light production from NCL in each mouse relative to luciferin. As
shown in Fig 5C the efficiency of probe uncaging in the NTR+ group was approximately an
order of magnitude higher than in the NTR- group (11.7±2.5% and 1.5±1.4% respectively;
p = 0.0001), demonstrating the utility of this probe for imaging of NTR activity in tumors.
In a previously reported study of NTR imaging with CytoCy5S fluorescence of orthotopic
xenograft tumors, probe activation by bacteria in the gastrointestinal tract (GIT) resulted in
background fluorescence in that cancer model requiring fluorescence lifetime gating to differ-
entiate tumor signal from GIT signal [24]. Although we have not presented results of orthoto-
pic tumors, it is anticipated that the bioluminescence based imaging tool in our study,
permitting detection of the signal only with coexpression of both luciferase and NTR, would
eliminate such issues.
Conclusions
In conclusion, these results demonstrate that the NCL probe can be effectively used for non-
invasive real-time imaging of NTR activity in vitro, in live bacteria and mammalian cells, as
well as in vivo, in preclinical models of cancer and certain bacterial infections (S1 Movie). This
novel reagent should significantly simplify screening of prodrugs in vivo and accelerate the pre-
clinical development of enzyme-activatable therapeutics for translation into the clinic.
Supporting Information
S1 Fig. Analysis of NCL reduction by E. coli nitroreductase in vitro. (a). UV HPLC profiles
(detected at 320 nm) of NCL reduction by NTR over 30 min, peak at 0.4 min corresponds to
luciferin (m/z 281), peak at 1.7 min corresponds to NCL (m/z 406). (b). Time course of the
conversion of NCL to luciferin, the distribution of reaction products was quantified by HPLC
analysis on the basis of absorbance at 320 nm. (c). Absorbance calibration curve for NCL. (d).
Pseudo-first-order kinetics of NCL reduction, rate constant 5.810-3 s-1, t1/2: 119.5 s.
(TIF)
S2 Fig. Kinetic measurements of NCL reduction by NTR in vitro. (a). Calibration curve for
luciferin fluorescence at λex/em = 330/530 nm. (b). Lineweaver–Burk plot of NCL probe reduc-
tion (5–50 μM) by NTR from E. coli NfsA (0.25 μg/mL) in the presence of NADH (500 μM) at
37°C in PBS buffer (pH 7.4). Kinetic parameters Km and Vmax were determined fromMichae-
lis-Menten model. (c). A plot of fluorescence intensity at λ330/530 of different amounts of NCL
(1–50 μM) over an incubation time of 15 min with 1 μg/mL of NTR from E. coli NfsA and
500 μM of NADH at 37°C in PBS buffer (pH 7.4). (d). A plot of fluorescence intensity at λ330/
530 of 20 μM of NCL, 500 μM of NADH and different amounts of NTR from E. coli NfsA
(0.05–0.2 μg/mL) over an incubation time of 20 min at 37°C in PBS buffer (pH 7.4).
(TIF)
S3 Fig. Inhibition of NTR activity by dicoumarol in vitro.NCL (20 μM) reduction by NTR
(0.5 μg/mL) in the presence of NADH (100 μM) was inhibited by dicoumarol (0 to 200 μM)
(Fig 2a). Inhibitory activity of dicoumarol is expressed as a percentage compared to uninhib-
ited control.
(TIF)
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S4 Fig. Bioluminescent imaging of nitroreductase with NCL in enzyme assay. Light emis-
sion from luciferin in the presence and absence of NTR, NTR did not have any effect on the
luciferin-luciferase reaction. Total luminescent signal integrated over 30 min from luciferin
(0.25–5 μM) with NADH (100 μM), luciferase (60 μg/mL) and NTR (10 μg/mL) compared to
the control (without NTR).
(TIF)
S5 Fig. Bioluminescence imaging of NTR by NCL in various E. coli strains. (a). Biolumines-
cence from 100 μMNCL probe incubated with the wild type AB1157 and luciferase expressing
AB1157 CBR E. coli strains (107 bacteria/mL) for 2 h at 37°C before imaging. The dotted line
indicates background, calculated as the average signal from wells containing bacteria only. (b).
Bioluminescence from NCL probe and luciferin (10 μM) incubated with luciferase expressing
E. coli AB1157 CBR (parent strain) and AB502NemA CBR NTR KO (mutant strain) (108 bac-
teria/mL) for 10 min before imaging. A significant difference in signal from the probe is
observed between parent and NTR mutant strains (p = 0.0062) while the luciferin signal is the
same. (c). Signal kinetics over 1 hour from 100 μMNCL and indicated concentrations of bacte-
ria/mL AB1157 CBR.
(TIF)
S6 Fig. NCL in vitro stability in mouse plasma. T1/2: 53.7 h.
(TIF)
S7 Fig. NCL in vitro stability in mouse liver microsomes. Testosterone was used as a positive
control.
(TIF)
S8 Fig. In vivo comparison of NCL kinetics after IP and IV administration in a mouse
model of thigh infection (luciferase and nitroredictase expressing E. coli). Luminescence
over 2 h from infected mice that received NCL as a percentage of luminescence from mice that
were injected with E. coli lux (positive control for bacterial number)5. Mice were infected with
5x107 E. coli, NCL was administered by IV or IP injection, n = 2–4 per group. Statistical analy-
sis was performed using a two way ANOVA with Bonferroni post-test showing no significant
difference between IV and IP administration of NCL. The error bars were calculated using the
following equation: Luminescence SEM
Average lux
 100:
(TIF)
S9 Fig. Fluorescent imaging of NTR with CytoCy5S probe in MDA-MB-231-NTR-Fluc-
EGFP and MDA-MB-231-luc cells. (a). The cells were incubated with 400 ng/mL of CytoCy5S
in HBSS or HBSS only (control) for 1.5 h, washed with HBSS once and imaged for fluorescence
(excitation 640 nm, emission 700 nm) in IVIS Spectrum. Error bars are ±SD of three wells,
P = 0.0006. (b). Image overlay of a photographic image and epi-fluorescence from the well
plate used in the assay.
(TIF)
S10 Fig. The CytoTox-Glo Cytotoxicity Assay (Promega).MDA-MB-231-luc cells were
treated with various concentrations of NCL for 1 h and the level of ATP was measured using
CytoTox-Glo reagent.
(TIF)
S11 Fig. Imaging of NTR with NCL in stably transfected cancer cells MDA-MB-231GFP+Luc
+NTR+ compared to the control cells (MDA-MB-231GFP+Luc+). (a). Bioluminescence from
NCL (50–5 μM) 15 min after addition to the cells. (b). Luciferin signal (50–5 μM) 15 min after
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addition to the cells confirmed equal levels of luciferase in both cell lines. Imaging was per-
formed for 1 h, a single image presented here is at 15 min time point.
(TIF)
S12 Fig. Imaging of NTR in subcutaneous xenograft model of cancer. Signal kinetics over 1
hour from luciferin and NCL in NTR+ and NTR- groups (n = 5).
(TIF)
S1 File. Contains chemical materials and methods, synthesis, spectra and general methods.
(DOCX)
S1 Movie. Animation movie demonstrates the concept of the study, probe design and appli-
cations.
(AVI)
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